Actelis Networks Files S-1/A for Resale, Faces Nasdaq Delisting Threat

TL;DR

**ASNS is teetering on the edge of delisting, making this warrant resale a high-risk play despite a recent capital injection.**

AI Summary

Actelis Networks, Inc. (ASNS) filed an S-1/A on December 10, 2025, primarily for the resale of 680,422 shares of common stock by selling stockholders, issuable upon warrant exercise. The company will not receive proceeds from these sales, but will benefit from cash warrant exercises. A significant development was the July 2025 Private Placement, which raised approximately $1 million in gross proceeds through the sale of 162,602 shares of common stock and associated Series A-3 and Series A-4 warrants, each with an exercise price of $6.15 per share. Shareholder approval for warrant issuance was obtained on November 7, 2025. The company also disclosed ongoing issues with Nasdaq listing compliance, having received a delist determination letter on March 27, 2024, for failing to meet the $2,500,000 Minimum Shareholders' Equity Requirement, necessitating a hearing before the Nasdaq Hearings Panel. A 10-for-1 reverse stock split was effected on November 18, 2025, to address listing requirements, with the common stock closing at $3.05 per share on December 9, 2025.

Why It Matters

This S-1/A filing is crucial for investors as it details the potential dilution from 680,422 shares entering the market via warrant exercises, though Actelis itself won't directly profit from these sales. The $1 million raised in the July 2025 Private Placement provides some capital, but the persistent Nasdaq delisting threat due to failing the $2.5 million Minimum Shareholders' Equity Requirement signals significant financial instability and could severely impact investor confidence and liquidity. Competitively, Actelis's focus on cyber-hardened, hybrid fiber networking for wide-area IoT is a niche, but its ability to execute and maintain public listing is paramount for future growth and market perception.

Risk Assessment

Risk Level: high — The risk level is high due to the explicit disclosure of a delist determination letter from Nasdaq on March 27, 2024, for non-compliance with the $2,500,000 Minimum Shareholders' Equity Requirement. This indicates severe financial distress and a significant threat to the company's public trading status. Furthermore, the filing highlights a 'history of losses and need for additional capital to fund our operations,' reinforcing the precarious financial position.

Analyst Insight

Investors should exercise extreme caution and thoroughly evaluate Actelis's ability to regain Nasdaq compliance and improve its financial standing. Given the delisting threat and history of losses, consider this a speculative investment and monitor the outcome of the Nasdaq Hearings Panel closely before making any decisions.

Key Numbers

• 680,422 — Shares of Common Stock (Shares for resale by selling stockholders upon warrant exercise)
• $1 million — Gross Proceeds (Raised from July 2025 Private Placement)
• 162,602 — Shares of Common Stock (Sold in July 2025 Private Placement)
• $6.15 — Exercise Price per share (For Series A-3 and Series A-4 Warrants)
• $2,500,000 — Minimum Shareholders' Equity Requirement (Nasdaq listing requirement not met by Actelis)
• 10-for-1 — Reverse Share Split (Effected on November 18, 2025)
• $3.05 — Closing Price per share (Of common stock on Nasdaq Capital Market on December 9, 2025)
• 7.0% — Cash Fee (Paid to Placement Agent for July 2025 Private Placement)
• 11,382 — Placement Agent Warrants (Shares issuable to Placement Agent)
• $7.688 — Exercise Price per share (For July 2025 Placement Agent Warrants)

Key Players & Entities

• Actelis Networks, Inc. (company) — Registrant
• Nasdaq Capital Market (regulator) — Stock exchange
• United States Securities and Exchange Commission (regulator) — Regulatory body
• Tuvia Barlev (person) — Chief Executive Officer and Chairman of the Board of Directors
• Eyal Peled, Esq. (person) — Legal counsel from Greenberg Traurig LLP
• H.C. Wainwright & Co., LLC (company) — Placement Agent for July 2025 Private Placement
• Nasdaq Hearings Panel (regulator) — Body reviewing delisting determination
• Greenberg Traurig LLP (company) — Legal counsel

FAQ

Risk Factors

• Nasdaq Listing Compliance [high — regulatory]: The company received a delist determination letter on March 27, 2024, for failing to meet the $2,500,000 Minimum Shareholders' Equity Requirement. A hearing before the Nasdaq Hearings Panel is pending, indicating ongoing uncertainty regarding continued listing on the Nasdaq Capital Market.
• Dependence on Warrant Exercises [medium — financial]: The current S-1/A filing is primarily for the resale of 680,422 shares issuable upon warrant exercise. While warrant exercises will bring cash to the company, the significant portion of shares being registered for resale suggests a reliance on these events for liquidity rather than core operational revenue.
• Dilution from Warrant Issuance [medium — financial]: The July 2025 Private Placement involved the sale of 162,602 shares and associated warrants. The issuance of additional warrants to the placement agent, exercisable at $7.688, presents a future dilution risk for existing shareholders.
• Reverse Stock Split Impact [medium — operational]: A 10-for-1 reverse stock split was effected on November 18, 2025, to address listing requirements. While intended to boost the share price (closing at $3.05 on December 9, 2025, post-split), reverse splits can sometimes be perceived negatively by the market and may not address underlying business performance issues.

Industry Context

Actelis Networks operates in the telecommunications infrastructure sector, providing solutions for network connectivity and management. The industry is characterized by rapid technological advancements, increasing demand for bandwidth, and intense competition from both established players and emerging technology providers. Companies in this space often face pressure to innovate and scale efficiently to meet evolving customer needs.

Regulatory Implications

The primary regulatory concern for Actelis is its compliance with Nasdaq listing rules. Failure to meet the Minimum Shareholders' Equity Requirement and the ongoing process with the Nasdaq Hearings Panel pose a significant risk of delisting, which would severely impact liquidity and investor confidence.

What Investors Should Do

1. Monitor Nasdaq Listing Status
2. Evaluate Warrant Exercise Impact
3. Assess Underlying Business Performance

Key Dates

• 2024-03-27: Received Nasdaq delist determination letter — Indicates failure to meet minimum shareholders' equity requirement, triggering a compliance process and potential delisting.
• 2025-07-01: July 2025 Private Placement — Raised approximately $1 million in gross proceeds through the sale of 162,602 shares and associated warrants, providing some immediate capital.
• 2025-11-07: Shareholder approval for warrant issuance — Necessary step to proceed with the issuance of warrants, including those related to the private placement and potential future exercises.
• 2025-11-18: 10-for-1 reverse stock split effected — Executed to comply with Nasdaq listing requirements, aiming to increase the per-share price.
• 2025-12-09: Common stock closing price of $3.05 — Reflects the post-reverse split share price, providing a current valuation reference point.
• 2025-12-10: Filed S-1/A for resale of shares — Registers shares for resale by selling stockholders, primarily from warrant exercises, indicating potential selling pressure and a focus on secondary market liquidity.

Glossary

S-1/A

An amendment to a registration statement filed with the SEC, typically used to update or correct information before an initial public offering or for other securities-related filings. (This filing indicates Actelis is updating or providing additional information related to its securities, specifically for the resale of shares by existing holders.)

Warrant Exercise

The act of a warrant holder purchasing shares of the company's stock at a predetermined price (the exercise price). (The resale of 680,422 shares is contingent upon these warrants being exercised, which will also provide cash to the company.)

Private Placement

A sale of securities directly to a select group of investors, rather than through a public offering. (Actelis raised $1 million through a private placement in July 2025, indicating a method used to secure capital outside of public markets.)

Reverse Stock Split

A corporate action where a company reduces the number of its outstanding shares by consolidating them, typically to increase the share price. (Actelis implemented a 10-for-1 reverse stock split to meet Nasdaq's minimum share price requirements.)

Minimum Shareholders' Equity Requirement

A threshold set by stock exchanges (like Nasdaq) that a company's total shareholders' equity must meet to remain listed. (Actelis failed to meet this $2,500,000 requirement, leading to a delisting warning.)

Year-Over-Year Comparison

Information comparing key metrics to a previous year's filing is not available in the provided context. The S-1/A focuses on the current registration of shares for resale and recent financing activities, rather than a year-over-year financial performance comparison.

Key Financial Figures

• $0.0001 — 2 shares of our common stock, par value $0.0001 per share, issuable upon the exercise o
• $3.05 — stock on the Nasdaq Capital Market was $3.05 per share. This prospectus gives effe
• $6.15 — f Common Stock, for a purchase price of $6.15 per share and related Common Warrants,
• $1 million — gregate gross proceeds of approximately $1 million. The July 2025 Private Placement closed
• $35,000 — ed by the Company from the Offering and $35,000 for accountable expenses to the placeme
• $7.688 — tock) at an exercise price per share of $7.688 which will be exercisable commencing on
• $2,500,000 — to our failure to maintain a minimum of $2,500,000 in shareholders’ equity (the &ldq
• $1.00 — tock to maintain a minimum bid price of $1.00 per share (the “Bid Price Rule&rd
• $11.8 — f June 20, 2029 at an exercise price of $11.8 per share (ii) 99,967 warrants issued o
• $20.0 — ecember 6, 2029 at an exercise price of $20.0 per share and (iii) 199,934 warrants is
• $17.5 — of July 2, 2026 at an exercise price of $17.5 per share (the “Existing Warrants
• $3.70 — on stock at a reduced exercise price of $3.70 per share in consideration of the Compa
• $1.6 million — gregate gross proceeds of approximately $1.6 million from the exercise of the Existing Warra

Filing Documents

• ea0268992-s1a1_actelis.htm (S-1/A) — 268KB
• ea026899201ex23-1_actelis.htm (EX-23.1) — 4KB
• image_001.jpg (GRAPHIC) — 13KB
• ex23-1_001.jpg (GRAPHIC) — 4KB
• 0001213900-25-120075.txt ( ) — 295KB

Use of Proceeds

Use of Proceeds 9 Selling Stockholders 10 Description of Offered Securities 12 Plan of Distribution 17 Legal Matters 18 Experts 18 Where You Can Find More Information 18 Incorporation by Reference 19 i ABOUT THIS PROSPECTUS This prospectus is part of a registration statement that we filed with the Securities and Exchange Commission (the “SEC”). The selling stockholders named in this prospectus may from time to time sell the securities described in the prospectus. You should read this prospectus together with the more detailed information regarding our company, our Common stock, and our financial statements and notes to those statements that appear elsewhere in this prospectus and any applicable prospectus supplement together with the additional information that we incorporate in this prospectus by reference, which we describe under the heading “Where You Can Find More Information.” You should rely only on the information contained in, or incorporated by reference in, this prospectus and in any accompanying prospectus supplement. We have not authorized anyone to provide you with different information from that contained in, or incorporated by reference in, this prospectus. You should not assume that the information in this prospectus or any prospectus supplement is accurate as of any date other than the date on the front of those documents or that any document incorporated by reference is accurate as of any date other than its filing date. You should not consider this prospectus to be an offer or solicitation relating to the securities in any jurisdiction in which such an offer or solicitation relating to the securities is not authorized. Furthermore, you should not consider this prospectus to be an offer or solicitation relating to the securities if the person making the offer or solicitation is not qualified to do so, or if it is unlawful for you to receive such an offer or solicitation. In this prospectus, we fr

Forward-looking statements

Forward-looking statements are based on our management’s current expectations, estimates, forecasts and projections about our business and the industry in which we operate and our management’s beliefs and assumptions, and are not guarantees of future performance or development and involve known and unknown risks, uncertainties and other factors that are in some cases beyond our control. As a result, any or all of our forward-looking include, among other things, those listed under “Risk Factors,” Use of Discussion and Analysis of Financial Condition and Results of Operations,” “Business” and elsewhere herein or by incorporation by reference. Potential investors are urged to consider these factors carefully in evaluating the forward-looking statements. You should read thoroughly this prospectus and the documents that we refer to with the understanding that our actual future results may be materially different from and worse than what we expect. We qualify all of our forward-looking statements by these cautionary statements. The forward-looking statements included in this prospectus speak only as of the date of this prospectus. Although we believe that the expectations reflected in the forward-looking in the forward-looking statements will be achieved or will occur. Except as required by law, we assume no obligation to update or revise these forward-looking statements for any reason, even if new information becomes available in the future. You should, however, review the factors and risks we describe in the reports we will file from time to time with the SEC after the date of this prospectus. See “Where You Can Find More Information.” O

View Full Filing

View this S-1/A filing on SEC EDGAR